suma/albumin

BACKGROUND OF THE INVENTION Biological fluids such as blood plasma or serum, milk whey, urine, etc. contain a mixture of several proteins. For example, blood plasma contains albumin (3.5-4.5 g/100 ml, M. wt 66,000), fibrinogen (0.20-0.45 g/100 ml, M. wt 340,000), .alpha.-globulins (0.4-1.0 g/100 ml)

TECHNICAL FIELD The present invention provides a pharmaceutical composition comprising albumin as an active ingredient. The composition of the present invention is useful for treatment of the conditions such as corneal and conjunctival lesion and dry eye. The composition of the present invention has

INCORPORATION-BY-REFERENCE OF MATERIAL ELECTRONICALLY SUBMITTED Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 30,551 bytes ASCII (Text) file named "702141SequenceListing.txt,"

TECHNICAL FIELD The present invention provides a pharmaceutical composition comprising albumin as an active ingredient. The composition of the present invention is useful for treatment of the conditions such as corneal and conjunctival lesion and dry eye. The composition of the present invention has

FIELD OF THE INVENTION The present invention relates to a method for suppressing coloring of human serum albumin expressed by genetic engineering. BACKGROUND OF THE INVENTION An albumin, particularly human serum albumin (hereinafter also referred to as HSA) is an important component constituting

TECHNICAL FIELD OF THE INVENTION This invention is related to the in vivo visualization of tissues and organs to determine complications of diabetes. It is also related to the treatment of diabetic complications with substances reactive with the fructosyllysine group in nonenzymatically glycated

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the manufacture and use of recombinant albumin fusion proteins and combinations thereof, and particularly to yeast expressed fusion proteins formed between human albumin and bioactive molecules such as therapeutic

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the manufacture and use of recombinant albumin fusion proteins and combinations thereof, and particularly to yeast expressed fusion proteins formed between human albumin and bioactive molecules such as therapeutic

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the manufacture and use of recombinant albumin fusion proteins and combinations thereof, and particularly to yeast expressed fusion proteins formed between human albumin and bioactive molecules such as therapeutic

This invention relates to a water-insoluble polymer having a large quantity of albumin bound thereto, a process for its production, and its use for the removal of noxious substances in plasma. Substances which adsorb proteins such as albumin have been known, and include, for example, such inorganic

FIELD OF THE INVENTION This invention relates in general to an animal model with serum attributes which have similar or identical properties and pharmokinetics with the human blood system in order to improve the assessment and development of new therapeutics and vaccines and to provide more reliable

CROSS-REFERENCES TO RELATED APPLICATION This patent application claims the benefit of priority under 35 U.S.C .sctn.119 of Korean Patent Application No. 10-2009-0049866 filed on Jun. 5, 2009, the contents of which are incorporated herein by reference. BACKGROUND OF THE INVENTION 1. Field of the

BACKGROUND OF THE INVENTION Factor VIII is a protein found in blood plasma which acts as a cofactor in the cascade of reactions leading to blood coagulation. A deficiency in the amount of Factor VIII activity in the blood results in the clotting disorder known as hemophilia A, an inherited condition

BACKGROUND OF THE INVENTION Factor VIII is a protein found in blood plasma which acts as a cofactor in the cascade of reactions leading to blood coagulation. A deficiency in the amount of Factor VIII activity in the blood results in the clotting disorder known as hemophilia A, an inherited condition

BACKGROUND OF THE INVENTION Factor VIII is a protein found in blood plasma which acts as a cofactor in the cascade of reactions leading to blood coagulation. A deficiency in the amount of Factor VIII activity in the blood results in the clotting disorder known as hemophilia A, an inherited condition